Jaber et al. conducted a retrospective study of 13 patients with RAI-R thyroid cancer who were treated with either single-agent or combination MEK/BRAF inhibitors and underwent 131-I diagnostic WBS during treatment [21]. This evidence concerns the gene BRAF and thyroid gland carcinoma.